Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike. JNJ raised guidance while headlines fixated on a 68,000-case talc litigation MDL. Pfizer reaffirmed its outlook and pushed harder into obesity and oncology. Two large-cap dividend payers, two very different setups for buyers today.
Oncology Powers JNJ. Padcev and Vyndaqel Carry Pfizer.
JNJ posted $24.062 billion in revenue, up 9.9%, with Innovative Medicine at $15.426 billion (+11.2%). DARZALEX cleared $3.964 billion (+22.5%), TREMFYA jumped 68.3%, and CARVYKTI grew 62.1%. STELARA cratered 59.7% from biosimilar erosion, and the portfolio still absorbed the hit.
Pfizer delivered $14.451 billion (+5.4%) with Specialty Care up 12% and Oncology up 9%. Padcev was the standout at $591 million (+39%). COVID kept dragging: Comirnaty down 59%, Paxlovid down 62%. CEO Albert Bourla said Pfizer is “positioned to lead” in oncology and obesity.
| Business Driver | JNJ | PFE |
| Growth engine | Oncology and immunology | Launched/acquired products +22% |
| Standout drug | DARZALEX +22.5% | Padcev +39% |
| Biggest drag | STELARA -59.7% | Paxlovid -62% |
One Sharpens Its Focus. One Bets the House on Obesity.
Joaquin Duato is stripping JNJ down to six priority areas, spinning DePuy Synthes within 18 to 24 months, and investing over $1 billion in next-gen cell therapy manufacturing in Pennsylvania. Guidance moved up to $100.8 billion in revenue and $11.55 in adjusted EPS.
Pfizer is going the other direction. Bourla dropped ~$7 billion on Metsera for ultra-long-acting GLP-1 obesity assets, added a $1.35B PD-1 x VEGF bispecific from 3SBio, and lined up ~20 pivotal study starts for 2026. The Vyndamax patent settlement pushed effective U.S. exclusivity to June 2031, defusing a real cliff.
Talc Charges vs. Obesity Readouts
JNJ absorbed $330 million in litigation charges in Q1 and still beat. Polymarket traders assign a 92% probability that JNJ beats again next report. The stock is up 26.71% year to date, while PFE sits at -1.52%. I want to see Padcev’s August 17, 2026 PDUFA land and Metsera Phase 3 data validate the obesity bet.
Why the Talc Noise Looks Like My Kind of Setup
I lean toward JNJ here. A 64 consecutive year dividend record, a 46% payout ratio backed by a $21 billion free cash flow target, and accelerating oncology growth are worth more to me than the litigation overhang costs. If you need income today, PFE’s 7.2% yield and 8x forward earnings offer a turnaround pitch, but the obesity thesis has to actually work. For steadier compounders, I would take the Dividend King while the courtroom headlines still cloud the price.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
